Drug Safety

Acknowledgement
pp. 1101-1103(3)
Author: Adis International Limited,

Restoring Confidence in Vaccines by Explaining Vaccine Safety Monitoring: Is a Targeted Approach Needed?
pp. 1105-1109(5)
Authors: Casiday, Rachel E.; Cox, Anthony R.

Reye's Syndrome: The Case For a Causal Link with Aspirin
pp. 1111-1121(11)
Author: Glasgow, John F.T.

Statins and Pancreatitis: A Systematic Review of Observational Studies and Spontaneous Case Reports
pp. 1123-1132(10)
Authors: Singh, Sonal; Loke, Yoon K.

Tolerability of Different Dosing Regimens of Bisphosphonates for the Treatment of Osteoporosis and Malignant Bone Disease
pp. 1133-1152(20)
Authors: Bobba, Raja S.; Beattie, Karen; Parkinson, Bill; Kumbhare, Dinesh; Adachi, Jonathan D.

Sirolimus-Associated Proteinuria and Renal Dysfunction
pp. 1153-1161(9)
Author: Rangan, Gopala K.

Fluvastatin and Hepatic Reactions: A Signal From Spontaneous Reporting in Italy
pp. 1163-1172(10)
Authors: Conforti, Anita; Magro, Lara; Moretti, Ugo; Scotto, Stefania; Motola, Domenico; Salvo, Francesco; Ros, Barbara; Leone, Roberto

Use and Safety of Anthroposophic Medications in Chronic Disease: A 2-Year Prospective Analysis
pp. 1173-1189(17)
Authors: Hamre, Harald J.; Witt, Claudia M.; Glockmann, Anja; Tröger, Wilfried; Willich, Stefan N.; Kiene, Helmut

Risk factors for Rhabdomyolysis with Simvastatin and Atorvastatin
pp. 1191-1191(1)
Authors: Golomb, Beatrice; Evans, Marcella

The Author's Reply
pp. 1191-1192(2)
Authors: Ronaldson, Kathlyn J.; Boyd, Ian W.